Edition:
United States

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

0.37USD
23 May 2018
Change (% chg)

$-0.01 (-2.20%)
Prev Close
$0.38
Open
$0.38
Day's High
$0.38
Day's Low
$0.36
Volume
73,274
Avg. Vol
121,315
52-wk High
$2.83
52-wk Low
$0.33

Chart for

About

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to... (more)

Overall

Beta: 0.14
Market Cap(Mil.): $17.24
Shares Outstanding(Mil.): 9.85
Dividend: --
Yield (%): --

Financials

  ONTX.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -2.62 -- --
ROI: -307.64 14.84 14.38
ROE: -4,335.58 16.34 16.07

BRIEF-Onconova Therapeutics Reports Q1 Loss Per Share Of $0.34

* ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR FIRST QUARTER 2018

May 15 2018

BRIEF-Oleg Nodelman Reports 9.99 Pct Passive Stake In Onconova Therapeutics As Of April 27, 2018

* OLEG NODELMAN REPORTS 9.99 PERCENT PASSIVE STAKE IN ONCONOVA THERAPEUTICS INC, AS OF APRIL 27, 2018 - SEC FILING Source text: (https://bit.ly/2KJY3o0) Further company coverage:

May 07 2018

BRIEF-Onconova Therapeutics Announces Pricing Of $25 Mln Upsized Underwritten Public Offering

* ONCONOVA THERAPEUTICS ANNOUNCES PRICING OF $25.0 MILLION UPSIZED UNDERWRITTEN PUBLIC OFFERING

Apr 27 2018

BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research 2018 Annual Meeting

* ONCONOVA PRESENTS DATA ON DUAL INHIBITOR OF CDK4/6 + ARK5 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH 2018 ANNUAL MEETING

Apr 19 2018

BRIEF-Onconova Therapeutics Says Offering Up To 18.5 Mln Units Of Common Stock, Warrants

* ONCONOVA THERAPEUTICS - OFFERING UP TO 18.5 MILLION UNITS (UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT) Source text (https://bit.ly/2J0SqAg) Further company coverage:

Apr 17 2018

BRIEF-Onconova Therapeutics Reports Full-Year 2017 Results

* ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 08 2018

BRIEF-Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH PINT PHARMA TO COMMERCIALIZE RIGOSERTIB FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA

Mar 05 2018

BRIEF-683 Capital Management Reports 21.8 Pct Stake In Onconova Therapeutics

* 683 CAPITAL MANAGEMENT LLC REPORTS 21.8 PERCENT STAKE IN ONCONOVA THERAPEUTICS INC AS OF FEB 8 - SEC FILING

Feb 16 2018

BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial

* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS

Jan 17 2018

BRIEF-Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI

* ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE

Jan 04 2018

Competitors

Earnings vs. Estimates